Inclusion Criteria:

- Histological documentation of adenocarcinoma of the prostate, with available biopsy
pathology. Material from this biopsy must be available for central review at DF/HCC
by the beginning of the second cycle of therapy.

- Potential candidate for radical prostatectomy

- Must meet one or more of the below characteristics: Gleason score of 8, 9 or 10;
serum PSA of greater than or equal to 20 ng/mL; clinical T stage of T3; PSA velocity
of greater than or equal to 2ng/mL/year in the year prior to diagnosis; Gleason score
of 7 and erMRI T3 disease; Greater than or equal to 50% of the total number of biopsy
cores positive for prostate cancer and either PSA > 10ng/mL or Gleason score of 7 or
clinical T stage of T2a, T2b or T2c.

- Greater than six weeks since any major surgery

- Serum testosterone > 100ng/dL

- ECOG Performance Status of 0 or 1

- ANC > 1,500/ul

- Platelets > 100,000/ul

- Total bilirubin, alkaline phosphatase, AST and ALT within normal limits

- Creatinine < 2.0 x upper limit of normal

Exclusion Criteria:

- History of prior radiation, surgery or hormonal therapy treatment for prostate cancer

- Clinical evidence of metastatic prostate cancer

- Ongoing oral steroid use

- Pre-existing neuropathy of grade 2 or greater

- Severe claustrophobia, inability to lie still in a magnet for 60 minutes, a
pacemaker, or any other condition that would preclude proximity to a strong magnet.

- History of the following conditions: unstable angina; symptomatic, clinically
significant peripheral vascular disease; NY Heart Association Grade 2 or greater
heart failure; uncontrolled hypertension; myocardial infarction or stroke < 12 months
prior to enrollment; uncontrolled hypertension; active, uncontrolled infection;
history of DVT, PE or known coagulopathy or bleeding diathesis; ongoing us of
anticoagulant therapy; history of abdominal fistulas, GI perforation, or
intra-abdominal abscess within 6 months prior to study entry; non-healing ulcer or
fracture; history of another malignancy diagnosed within the last five years; spot
urine protein: creatinine ratio > 1.0 at screening.